CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
Tesetaxeldrug
Likely dose
Tesetaxel 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01064713
NCT01064713Phase 2Completed
CompareCT.gov

A Phase II Study of Tesetaxel as Second-line Therapy for Subjects With Advanced Melanoma and Normal Serum LDH

M.D. Anderson Cancer Center·interventional·Posted Feb 8, 2010·Updated Jul 17, 2018

In Brief

A Phase 2 clinical trial evaluating Tesetaxel for Advanced Melanoma and Cancer. Completed, enrolled 17 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if tesetaxel can help to control metastatic melanoma. The safety of this drug will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Melanoma, Cancer
CountriesUnited States
CollaboratorsGenta Incorporated

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 8, 2010
Enrollment StartFeb 1, 2010
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 16.4 years ago

Interventions

Tesetaxeldrug

Cohort A: 40 mg by mouth every 21 days. Cohort B. 50 mg by mouth every 21 days.